• 1
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiologic studies. Lancet 1996; 347: 171327.
  • 2
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 104759.
  • 3
    Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 32133.
  • 4
    Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 60616.
  • 5
    American Cancer Society. Breast cancer facts and figures 2003–2004. Atlanta: American Cancer Society, 2003.
  • 6
    Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350: 143041.
  • 7
    Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathological findings from the National Surgical Adjuvant Breast and Bowel Project—twelve-year observations concerning lobular carcinoma in situ. Cancer 2004; 100: 23844.
  • 8
    Toniolo P, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 1907.
  • 9
    Toniolo PG, Pasternack BS, Shore RE, Sonnenschein EG, Koenig KL, Rosenberg C, Strax P, Strax S. Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat 1991; 18: S236.
  • 10
    Rinaldi S, Dechaud H, Biessy C, Morin-Raverot V, Toniolo P, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Secreto G, Ciampi A, Riboli E, Kaaks R. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001; 10: 75765.
  • 11
    Breslow NE, Day NE. Statistical methods in cancer research. vol. 1. IARC Sci Publ 32. Lyon: IARC, 1980.
  • 12
    Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997; 16: 234980.
  • 13
    Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P. Postmenopausal levels of estrogen, androgen, and SHBG and breast cancer risk: long-term results of a prospective study. Br J Cancer 2004; 90: 1539.
  • 14
    Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000; 27: 6773.
  • 15
    Zelen M. Theory of early detection of breast cancer in the general population. In: HensenJC, MattheiemWH, RozencweigM, eds. Trends in research and treatment. New York: Raven, 1976. 287300.
  • 16
    Morrison AS. The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening. Int J Epidemiol 1982; 11: 2617.
  • 17
    Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, Di Palma S, Rilke F. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994; 11: 22335.
  • 18
    Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995; 76: 1197200.
  • 19
    Polyak K. On the birth of breast cancer. Biochim Biophys Acta 2001; 1552: 113.
  • 20
    Ernster VL, Ballard-Barbash R, Barlow W, Zheng B, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94: 154654.
  • 21
    UK Trial of Early Detection of Breast Cancer Group. 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet 1999; 353: 190914.
  • 22
    Seidman H, Gelb SK, Silverberg E, LaVerda N, Lubera JA. Survival experience in the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 1987; 37: 25890.
  • 23
    Rosenberg RD, Lando JF, Hunt WC, Darling RR, Williamson MR, Linver MN, Gilliland FD, Key CR. The New Mexico Mammography Project: screening mammography performance in Albuquerque, New Mexico, 1991–1993. Cancer 1996; 78: 17319.
  • 24
    Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96: 90620.
  • 25
    Bernstein L. The epidemiology of breast carcinoma in situ. In: SilversteinM, RechtA, LagiosM, eds. Ductal carcinoma in situ of the breast. Philadelphia: Lippincott Williams & Wilkins, 2002. 2234.
  • 26
    Endogenous Hormones and Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 121826.